Abstract
The majority of the chemotherapeutic drugs currently employed do not act exclusively into the target areas, which results in a series undesired effects to the patients. This scenario requires the design of strategies to overcome these drawbacks. The MIT research group lead by Prof. Michael F. Rubner and Prof. Robert E. Cohen has been developing through the layer-by-layer technique a new d…